바이오포토닉스 시장 : 기술별, 용도별, 최종 용도별 - 세계 예측(2024-2032년)

Global Biophotonics Market size will register a 10.9% CAGR from 2024 to 2032, owing to the increasing demand for non-invasive diagnostics and rising healthcare spending. Non-invasive diagnostic methods, such as advanced imaging and light-based therapies, offer patients and providers less intrusive options with faster recovery times and improved comfort. Also, growing healthcare budgets enable investment in cutting-edge technologies and innovative solutions. This combination of heightened demand for non-invasive techniques and increased financial resources for medical advancements fosters substantial growth in the biophotonics industry, supporting its expansion and development.

For instance, in March 2024, BioPhotas, Inc. introduced the Celluma CONTOUR, an FDA-cleared light therapy device for body contouring, aging skin, and pain management, marking a significant advancement in light-based treatments. The FDA clearance of this device underscores the increasing regulatory support and validation for biophotonics applications. This advancement reflects a broader trend of integrating light therapy into mainstream medical practices, potentially driving market expansion and encouraging further investment and research in biophotonics technologies.

The biophotonics market is divided based on technology, application, end-use, and region.

The medical diagnostics segment will witness remarkable expansion through 2032 due to its crucial role in enhancing diagnostic accuracy and efficiency. Advances in biophotonics technologies, such as optical imaging and fluorescence-based techniques, significantly improve disease detection and monitoring. The growing demand for early and precise diagnostic tools drives adoption, as these technologies offer non-invasive and highly sensitive solutions. Additionally, increasing investments in research and development for innovative diagnostic applications further bolster the segment's dominance in the biophotonics industry.

The light therapy segment will garner considerable gains by 2032, attributed to its growing application in treating a range of medical conditions and improving patient outcomes. Advances in light therapy technologies offer non-invasive, effective solutions for pain management, skin disorders, and mood disorders. The increasing awareness of the benefits of light-based treatments, coupled with rising demand for alternative and complementary therapies, drives substantial growth in this segment. The expanding range of therapeutic applications and technological innovations further solidify its position in the market.

Europe biophotonics market share will reach a noteworthy CAGR during 2024 and 2032, propelled by its robust healthcare infrastructure, advanced research capabilities, and a strong emphasis on medical innovation. The region's extensive investment in biophotonics research and development, coupled with supportive government policies and a growing demand for advanced diagnostic and therapeutic solutions, drives significant market growth. Europe's established network of leading academic and research institutions, along with its proactive approach to integrating cutting-edge technologies, makes it a notable contributor to the biophotonics industry.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Forecast calculation
• 1.4 Data sources
  • 1.4.1 Primary
  • 1.4.2 Secondary
    • 1.4.2.1 Paid sources
    • 1.4.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360º synopsis, 2021 - 2032

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Vendor matrix
• 3.3 Profit margin analysis
• 3.4 Technology & innovation landscape
• 3.5 Patent analysis
• 3.6 Key news and initiatives
• 3.7 Regulatory landscape
• 3.8 Impact forces
  • 3.8.1 Growth drivers
    • 3.8.1.1 Advancements in technology
    • 3.8.1.2 Rising demand for non-invasive diagnostic techniques
    • 3.8.1.3 Increasing applications in life sciences
    • 3.8.1.4 Government initiatives and funding
    • 3.8.1.5 Rising demand for personalized medicine
  • 3.8.2 Industry pitfalls & challenges
    • 3.8.2.1 High cost of technology
    • 3.8.2.2 Complex regulatory environment
• 3.9 Growth potential analysis
• 3.10 Porter's analysis
  • 3.10.1 Supplier power
  • 3.10.2 Buyer power
  • 3.10.3 Threat of new entrants
  • 3.10.4 Threat of substitutes
  • 3.10.5 Industry rivalry
• 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategic outlook matrix

Chapter 5 Market Estimates & Forecast, By Technology, 2021 - 2032 (USD Billion)

• 5.1 In-vitro
• 5.2 In-vivo

Chapter 6 Market Estimates & Forecast, By Application, 2021 - 2032 (USD Billion)

• 6.1 See-through imaging
• 6.2 Microscopy
• 6.3 Inside imaging
• 6.4 Spectro molecular
• 6.5 Analytics sensing
• 6.6 Light therapy
• 6.7 Surface imaging
• 6.8 Biosensors

Chapter 7 Market Estimates & Forecast, By End Use, 2021 - 2032 (USD Billion)

• 7.1 Tests and components
• 7.2 Medical therapeutics
• 7.3 Medical diagnostics
• 7.4 Non-medical application

Chapter 8 Market Estimates & Forecast, By Region, 2021 - 2032 (USD Billion)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 UK
  • 8.3.2 Germany
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 South Korea
  • 8.4.5 ANZ
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 MEA
  • 8.6.1 UAE
  • 8.6.2 South Africa
  • 8.6.3 Saudi Arabia
  • 8.6.4 Rest of MEA

Chapter 9 Company Profiles

• 9.1 Affymetrix Inc. (Thermo Fisher Scientific Inc.)
• 9.2 Becton, Dickinson and Company
• 9.3 Carl Zeiss AG
• 9.4 Glenbrook Technologies
• 9.5 Hamamatsu Photonics K.K
• 9.6 IDEX
• 9.7 IPG Photonics Corporation
• 9.8 NU Skin Enterprises
• 9.9 Olympus Corporation
• 9.10 Oxford Instruments PLC
• 9.11 PerkinElmer Inc.
• 9.12 Thermo Fisher Scientific
• 9.13 TOSHIBA CORPORATION
• 9.14 Zecotek Photonics Inc.
• 9.15 ZEISS Group
• 9.16 Zenalux Biomedical Inc.